EPITOGENESIS INC — Department of Health and Human Services SBIR Phase I: NIAID
EPITOGENESIS INC — SBIR Phase I award from Department of Health and Human Services.
- Amount
- $600,000
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Topic
- NIAID
- NAICS
- —
- Place of performance
- CT
- Period
- —
Description
Bronchial asthma is a chronic respiratory disease that can be lethalAsthma is a global health problemAccording to the CDCin USAthere are currentlymillion asthma sufferers and this number is increasingHalf of the asthma patients have at least one hospitalization per yearwith an annual medical cost of $BTraditionallyasthma is treated during flare ups with prescribed inhaled corticosteriodsIn recent yearsvarious forms of immunotherapiessuch as sublingual treatment with large doses of allergens have been used to alleviate symptomsIn modern vaccine adjuvant researchthe concept of allergen specific therapeutic allergy vaccines are introducedWe previously developed an immune enhancing vaccine adjuvant formulationbased on the synergy between vitamins A and E and a flavonoid as an oil in water emulsionNIDSand obtained safety and protective efficacy as well as long term shelf stability results for rather result in antigen specific suppression of serum antibody responses following intra muscular vaccinationsThistogether with the fact that the components used can be anti inflammatorylead us to design a therapeutic allergy vaccine adjuvant platform as proposed herein